Compositions and methods for inhibiting fibrosis
Provided herein are compositions and methods for treating or preventing fibrosis.
1. A method for reducing idiopathic pulmonary fibrosis in a subject, the method comprising administering to a subject having idiopathic pulmonary fibrosis a therapeutically effective amount of a proline-glycine-proline (PGP)-containing peptide.
2. The method of claim 1 , wherein the PGP-containing peptide is selected from the group consisting of acetylated PGP (Ac-PGP), PGP, tert-butyloxycarbonyl (t-Boc) PGP, N-acetyl-PGPPGPPGPPGPPGLG (SEQ ID NO: 1) and APGPR (SEQ ID NO: 2).
3. The method of claim 1 , wherein the therapeutically effective amount of the PGP-containing peptide inhibits myofibroblast activity.
4. The method of claim 1 , further comprising administering to the subject an agent that inhibits angiotensin converting enzyme (ACE).
5. The method of claim 4 , wherein the ACE inhibitor is administered by oral inhalation, nasal inhalation, or intranasal mucosal administration.
6. The method of claim 5 , wherein the ACE inhibitor is administered orally, via an inhaler, a nebulizer or a nasal sprayer.
7. The method of claim 1 , wherein the PGP-containing peptide is administered by oral inhalation, nasal inhalation, or intranasal mucosal administration.
8. The method of claim 7 , wherein the PGP-containing peptide is administered via an inhaler, a nebulizer or a nasal sprayer.